The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
Open accessAbstract
Purpose: This phase II study of sorafenib, an oral multikinase inhibitor that targets Raf kinase and receptor tyrosine kinases, assessed efficacy, toxicity, pharmacokinetics, and biomarkers in advanced hepatocellular carcinoma (HCC) patients. Methods: Patients with inoperable HCC, no prior systemic treatment, and Child–Pugh (CP) A or B, received continuous, oral sorafenib 400 mg bid in 4-week cycles. Tumor response was assessed every two cycles using modified WHO criteria. Sorafenib pharmacokinetics were measured in plasma samples. Biomarker analysis included phosphorylated extracellular signal regulated kinase (pERK) in pretreatment biopsies (immunohistochemistry) and blood-cell RNA expression patterns in selected patients. Results: Of 137 patients treated (male, 71%; median age, 69 years), 72% had CP A, and 28% had CP B. On the basis of independent assessment, three (2.2%) patients achieved a partial response, eight (5.8%) had a minor response, and 46 (33.6%) had stable disease for at least 16 weeks. Investigator-assessed median time to progression (TTP) was 4.2 months, and median overall survival was 9.2 months. Grade 3/4 drug-related toxicities included fatigue (9.5%), diarrhea (8.0%), and hand–foot skin reaction (5.1%). There were no significant pharmacokinetic differences between CP A and B patients. Pretreatment tumor pERK levels correlated with TTP. A panel of 18 expressed genes was identified that distinguished “nonprogressors” from “progressors” with an estimated 100% accuracy. Conclusion: Although single-agent sorafenib has modest efficacy in HCC, the manageable toxicity and mechanisms of action support a role for combination regimens with other anticancer agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Self-citationAsymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Rising Incidence of Hepatocellular Carcinoma in the United States
El-Serag, H. B., & Mason, A. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401001 · Cited by 2,853
Estimates of the worldwide incidence of 25 major cancers in 1990
Parkin, Pisani, P., & Ferlay, J. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990315)80:6<827::aid-ijc6>3.0.co;2-p · Cited by 2,037
Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.124 · Cited by 872
Self-citationPhosphorylation of the MAP Kinase ERK2 Promotes Its Homodimerization and Nuclear Translocation
Khokhlatchev, A. V., Canagarajah, B., Wilsbacher, J., Robinson, M., Atkinson, M., Goldsmith, E., & Cobb, M. H. (1998) · Cell · doi:10.1016/s0092-8674(00)81189-7 · Cited by 677
Yeo, W., Mok, T. S., Zee, B., Leung, T. W. T., Lai, P. B. S., Lau, W. Y., Koh, J., Mo, F. K. F., Yu, S. C. H., Chan, A. T., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji315 · Cited by 590
International trends and patterns of primary liver cancer
McGlynn, K. A., Tsao, L., Hsing, A. W., Devesa, S. S., & Fraumeni, J. F. (2001) · International Journal of Cancer · doi:10.1002/ijc.1456 · Cited by 349
Huynh, H., Nguyen, T. T. T., Chow, K.-H. K.-P., Tan, P. H., Soo, K. C., & Tran, E. (2003) · BMC Gastroenterology · doi:10.1186/1471-230x-3-19 · Cited by 289
Leung, T. W. T., Patt, Y. Z., Lau, W. Y., Ho, S. K. W., Yu, S. C. H., Chan, A. T. �., Mok, T. S. K., Yeo, W., Liew, C.-T., Leung, N. W. Y., et al. (1999) · PubMed · Cited by 278
Qin, L.-X., & Tang, Z.-Y. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0572-9 · Cited by 201
Hofmann, W.-K., de Vos, S., Elashoff, D., Gschaidmeier, H., Hoelzer, D., Koeffler, H. P., & Ottmann, O. G. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07678-x · Cited by 194
Llovet, J. M., Bruix, J., & Gores, G. J. (2000) · Hepatology · doi:10.1053/he.2000.6959 · Cited by 180
Giambartolomei, S., Covone, F., Levrero, M., & Balsano, C. (2001) · Oncogene · doi:10.1038/sj.onc.1204372 · Cited by 133
Jiang, W., Lu, Z., He, Y., & Diasio, R. B. (1997) · PubMed · Cited by 113
Yoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Noguchi, R., Hicklin, D. J., Wu, Y. L., Yanase, K., Namisaki, T., Kitade, M., et al. (2004) · Hepatology · doi:10.1002/hep.20218 · Cited by 106
DePrimo, S. E., Wong, L. M., Khatry, D., Nicholas, S. L., Manning, W. C., Smolich, B. D., O’Farrell, A.-M., & Cherrington, J. M. (2003) · BMC Cancer · doi:10.1186/1471-2407-3-3 · Cited by 100
Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma
Lee, J., Park, J. O., Kim, W. S., Park, S. H., Park, K. W., Choi, M. S., Lee, J. H., Koh, K. C., Paik, S. W., Yoo, B. C., et al. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0837-7 · Cited by 83
MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis
Chenivesse, X., Franco, D., & Bréchot, C. (1993) · Journal of Hepatology · doi:10.1016/s0168-8278(05)80243-0 · Cited by 71
Richly, H., Kupsch, P., Passage, K. J., Grubert, M., Hilger, R. A., Voigtmann, R., Schwartz, B. E., Brendel, E., Christensen, O., Haase, C. G., et al. (2004) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp42650 · Cited by 51
Self-citationKurokawa, Y., Matoba, R., Nagano, H., Sakon, M., Takemasa, I., Nakamori, S., Dono, K., Umeshita, K., Ueno, N., Ishii, S., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0243 · Cited by 50
Cited by
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationEASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“Following an initial phase II study showing a signal of efficacy [322], a large double-blinded placebo controlled phase III investigation was conducted, leading to positive survival results [168].”
BackgroundBenson, A. B., Abrams, T. A., Ben-Josef, E., Bloomston, P. M., Botha, J. F., Clary, B. M., Covey, A., Curley, S. A., D'Angelica, M. I., Davila, R., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0027 · Cited by 2,268
Metadata
- Authors
- Abou-Alfa, G. K., Schwartz, L., Ricci, S., Amadori, D., Santoro, A., Figer, A., De Greve, J., Douillard, J.-Y., Lathia, C., Schwartz, B., Taylor, I., Moscovici, M., & Saltz, L. B.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-09-10
- Volume
- 24
- Issue
- 26
- Pages
- 4293-4300
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2156871508
- Cited by
- 1,195
- References
- 21
- FWCI
- 64.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.